Diagnostic Utility of Claudin-4 Immunohistochemistry in Distinguishing Adenocarcinoma Cells from Reactive Mesothelial Cells in Effusion Cytology

Mihira Ginnavaram, Pramod Kumar Pamu, Swetha Kesarapu, Narayanan Ramakrishna

Abstract


Background: Differentiating adenocarcinoma cells from reactive mesothelial cells in cases of effusion remains a diagnostic challenge due to overlapping morphological features. Claudin-4, a tight junction protein expressed in epithelial but absent in mesothelial cells, has emerged as a potential immunohistochemical (IHC) marker for this distinguishing between these cell types.

Objective: to evaluate the diagnostic utility of Claudin-4 immunohistochemistry in differentiating adenocarcinoma cells from reactive mesothelial cells in effusion cytology.

Methods: This prospective study was conducted at the Department of Pathology, Nizam’s Institute of Medical Sciences, Hyderabad, India, between June 2023 and December 2024. A total of 77 formalin-fixed paraffin-embedded cell block samples from effusion fluids (pleural, ascitic, and peritoneal) were analyzed. Inclusion criteria comprised cases diagnosed as malignant or reactive on cytology. Claudin-4 immunostaining was performed by using  EP417 clone. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of Claudine for differentiating malignant versus non-malignant effusion was calculated.

Results: Out of the 77 studied cases, 57 were malignant and 20 were non-malignant. Claudin-4 showed positive membranous staining in 50/57 malignant cases (87.72%) and in none of the non-malignant cases (100% specificity). The PPV was 100%, and NPV was 74.10%. Pulmonary adenocarcinoma was the most common malignancy showing Claudin-4 positivity. Claudin demonstrated excellent specificity for diagnosis of malignant effusions. 

Conclusion: Claudin-4 immunohistochemistry is highly specific as a reliable marker for differentiating malignant cells from reactive mesothelial cells. Its high specificity and positive predictive value make it a valuable diagnostic tool. However, a negative Claudin-4 immunohistochemistry results should be interpreted cautiously, particularly in clinically suspicious cases.


Keywords


Adenocarcinoma; claudin-4; effusion cytology; immunohistochemistry; mesothelial cells

References


  1. Halimi M, Beheshti-Rouy S, Salehi D, Rasihashemi SZ. The role of immunohistochemistry studies in distinguishing malignant mesothelioma from metastatic lung carcinoma in malignant pleural effusion. Iran J Pathol. 2019;14(2):122–6. doi:10.30699/ijp.14.2.122
  2. Pereira TC, Saad RS, Liu Y, Silverman JF. The diagnosis of malignancy in effusion cytology: a pattern recognition approach. Adv Anat Pathol. 2006;13(4):174-84. doi:10.1097/00125480-200607000-00004
  3. Fujiwara-Tani R, Mori S, Ogata R, Sasaki R, Ikemoto A, Kishi S, et al. Claudin-4: a new molecular target for epithelial cancer therapy. Int J Mol Sci. 2023;24(6):5494. doi:10.3390/ijms24065494
  4. Dithmer S, Blasig IE, Fraser PA, Qin Z, Haseloff RF. The basic requirement of tight junction proteins in blood-brain barrier function and their role in pathologies. Int J Mol Sci. 2024;25(11):5601. doi:10.3390/ijms25115601
  5. Monaco S, Mehrad M, Dacic S. Recent advances in the diagnosis of malignant mesothelioma: focus on approach in challenging cases and in limited tissue and cytologic samples. Adv Anat Pathol. 2018;25(1):24-30. doi:10.1097/pap.0000000000000176
  6. Jo VY, Cibas ES, Pinkus GS. Claudin-4 immunohistochemistry is highly effective in distinguishing adenocarcinoma from malignant mesothelioma in effusion cytology. Cancer Cytopathol. 2014;122(4):299-306. doi:10.1002/cncy.21392
  7. Soini Y, Kinnula V, Kahlos K, Pääkkö P. Claudins in differential diagnosis between mesothelioma and metastatic adenocarcinoma of the pleura. J Clin Pathol. 2006;59(3):250-4. doi:10.1136/jcp.2005.028589
  8. Patel A, Borczuk AC, Siddiqui MT. Utility of claudin-4 versus BerEP4 and B72.3 in pleural fluids with metastatic lung adenocarcinoma. J Am Soc Cytopathol. 2020;9(3):146-51. doi:10.1016/j.jasc.2019.12.003
  9. Kleinaki M, Vey JA, Awounvo S, Ishak A, Arnaouti M, Ryu HS, et al. The diagnostic accuracy of claudin-4 immunochemistry in differentiating metastatic carcinomas from mesothelial processes in serous effusion cytology: a systematic review and meta-analysis. Arch Pathol Lab Med. 2025;149(4):381-8. doi:10.5858/arpa.2023-0560-RA
  10. Najjar S, Gan Q, Stewart J, Sneige N. The utility of claudin-4 versus MOC-31 and Ber-EP4 in the diagnosis of metastatic carcinoma in cytology specimens. Cancer Cytopathol. 2023;131(4):245-53. doi:10.1002/cncy.22672
  11. Elhosainy A, Hafez MMA, Yassin EH, Adam M, Elnaggar MS, Aboulhagag NA. Diagnostic value of claudin-4 and EZH2 immunohistochemistry in effusion cytology. Asian Pac J Cancer Prev. 2022;23(8):2779-85. doi:10.31557/apjcp.2022.23.8.2779
  12. Afshar-Moghaddam N, Heidarpour M, Dashti S. Diagnostic value of claudin-4 marker in pleural and peritoneal effusion cytology: does it differentiate between metastatic adenocarcinoma and reactive mesothelial cells? Adv Biomed Res. 2014;3:161. doi:10.4103/2277-9175.138888
  13. Tessier-Cloutier B, Soslow RA, Stewart CJR, Köbel M, Lee CH. Frequent loss of claudin-4 expression in dedifferentiated and undifferentiated endometrial carcinomas. Histopathology. 2018;73(2):299-305. doi:10.1111/his.13525
  14. Naso JR, Churg A. Claudin-4 shows superior specificity for mesothelioma vs non-small-cell lung carcinoma compared with MOC-31 and Ber-EP4. Hum Pathol. 2020;100:10-4. doi:10.1016/j.humpath.2020.04.005
  15. Haque M, Kaur H, Wang M, Cai G. Comparative assessment of claudin-4, MOC-31, and BerEP4 immunomarkers in diagnostic workup of metastatic carcinoma in serous fluid specimens. Lab Invest. 2025;105(3):341-52. doi:10.1016/j.labinv.2024.102568




DOI: https://doi.org/10.15850/ijihs.v13n2.4561

Article Metrics

Abstract view : 0 times



 

This Journal indexed by

                   

 


Creative Commons License
IJIHS is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License



View My Stats